Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Tech Journal.
Press releases published on August 25, 2025
Propanc Biopharma Provides Shareholder Update
GlobeNewswire
·
August 25, 2025
MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today …
Synaptics To Participate at Upcoming Investor Conferences on Thursday, August 28, 2025 and Thursday, September 4, 2025
GlobeNewswire
·
August 25, 2025
SAN JOSE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) today announced its participation in upcoming investor conferences. Ken Rizvi, CFO, will participate at the Deutsche Bank’s Technology Conference on Thursday, August …
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
GlobeNewswire
·
August 25, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today …
Climb Bio to Present at Upcoming September 2025 Investor Conferences
GlobeNewswire
·
August 25, 2025
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in …
iBio Announces Closing of $50 Million Public Offering
GlobeNewswire
·
August 25, 2025
Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge …
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
GlobeNewswire
·
August 25, 2025
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making …
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
GlobeNewswire
·
August 25, 2025
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. …
Jade Biosciences to Participate in Upcoming Conferences
GlobeNewswire
·
August 25, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
GlobeNewswire
·
August 25, 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
GlobeNewswire
·
August 25, 2025
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in …
Golf Superstore Uses Descartes Sellercloud™ to Unify Omnichannel Operations
GlobeNewswire
·
August 25, 2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Chattanooga-based Golf Superstore is using Descartes Sellercloud™ integrated …
Crafting Seamless Notifications: How EngageLab’s Chrome Extension WebPush Is Transforming User Engagement and Extension Efficiency
GlobeNewswire
·
August 25, 2025
SINGAPORE, Aug. 25, 2025 (GLOBE NEWSWIRE) -- EngageLab launches industry-leading WebPush support for Chrome Extensions, empowering developers and businesses to reach users with real-time, high-impact notifications—no extra permissions, no missed …
Server PSU Supplier Linklieo Expands Global CRPS and Common Redundant Power Solutions
GlobeNewswire
·
August 25, 2025
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Linklieo, a leading server power supply supplier, today announced the expansion of its advanced server PSU, server power supply, and CRPS power supply product lines. Known for delivering dependable and high- …
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
GlobeNewswire
·
August 25, 2025
Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmology Sebastian Wolf, M.D …
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
GlobeNewswire
·
August 25, 2025
Total equity and debt raising of ~$90 million provides runway to 2H 2027 Strong support from existing and new investors including SPRIM Global Investments Funds will be used to scale-up production of needle-free vaccination delivery technology Founding CEO …
BetSymphony Unites Voice, AI, and Personalization to Create the First Conversational Frontend in iGaming
GlobeNewswire
·
August 25, 2025
AMSTERDAM, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BetSymphony just raised the bar for iGaming. The no-revenue-share iGaming platform has introduced a next-generation Conversational AI interface, powered by its advanced AI agent BetHarmony, now delivering a …
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
GlobeNewswire
·
August 25, 2025
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) …
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
GlobeNewswire
·
August 25, 2025
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to …
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
GlobeNewswire
·
August 25, 2025
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports …
Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis
GlobeNewswire
·
August 25, 2025
Saint Herblain (France), le 25 août, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA) a suspendu la licence d’IXCHIQ®, …